Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Young Website

Matthew R. Young, Ph.D.

Selected Publications

1)  Li W, Hua B, Saud SM, Lin H, Hou W, Matter MS, Jia L, Colburn NH, Young MR.
Berberine regulates AMP-activated protein kinase signaling pathways and inhibits colon tumorigenesis in mice.
Mol. Carcinog. [Epub ahead of print], 2014.
2)  Saud SM, Young MR, Jones-Hall YL, Ileva L, Evbuomwan MO, Wise J, Colburn NH, Kim YS, Bobe G.
Chemopreventive activity of plant flavonoid isorhamnetin in colorectal cancer is mediated by oncogenic Src and ß-catenin.
Cancer Res. 73: 5473-84, 2013.
3)  Mitsunaga M, Kosaka N, Choyke PL, Young MR, Dextras CR, Saud SM, Colburn NH, Sakabe M, Nagano T, Asanuma D, Urano Y, Kobayashi H.
Fluorescence endoscopic detection of murine colitis-associated colon cancer by topically applied enzymatically rapid-activatable probe.
Gut. 62: 1179-86, 2013.
4)  Young MR, Ileva LV, Bernardo M, Riffle LA, Jones YL, Kim YS, Colburn NH, Choyke PL.
Monitoring of tumor promotion and progression in a mouse model of inflammation-induced colon cancer with magnetic resonance colonography.
Neoplasia. 11: 237-46, 2009.
5)  Urano Y, Sakabe M, Kosaka N, Ogawa M, Mitsunaga M, Asanuma D, Kamiya M, Young MR, Nagano T, Choyke PL, Kobayashi H.
Rapid cancer detection by topically spraying a ?-glutamyltranspeptidase-activated fluorescent probe.
Sci Transl Med. 3: 110ra119, 2011.
6)  Wu L, Jiang H, Chawsheen HA, Mishra M, Young MR, Gerard M, Toledano MB, Colburn NH, Wei Q.
Tumor promoter-induced sulfiredoxin is required for mouse skin tumorigenesis.
Carcinogenesis. [Epub ahead of print], 2014.
7)  Hwang S, Baker AR, Young MR, Colburn NH.
Tumor suppressor PDCD4 inhibits NF-?B-dependent transcription in human glioblastoma cells by direct interaction with p65.
Carcinogenesis. [Epub ahead of print], 2014.
8)  Sun L, Mathews LA, Cabarcas SM, Zhang X, Yang A, Zhang Y, Young MR, Klarmann KD, Keller JR, Farrar WL.
Epigenetic Regulation of SOX9 by the NF-?B Signaling Pathway in Pancreatic Cancer Stem Cells.
Stem Cells. 31: 1454-66, 2013.
9)  Wei Q, Jiang H, Baker A, Dodge LK, Gerard M, Young MR, Toledano MB, Colburn NH.
Loss of sulfiredoxin renders mice resistant to azoxymethane/dextran sulfate sodium-induced colon carcinogenesis.
Carcinogenesis. 34: 1403-10, 2013.
10)  Camalier CE, Yi M, Yu LR, Hood BL, Conrads KA, Lee YJ, Lin Y, Garneys LM, Bouloux GF, Young MR, Veenstra TD, Stephens RM, Colburn NH, Conrads TP, Beck GR.
An integrated understanding of the physiological response to elevated extracellular phosphate.
J. Cell. Physiol. 2012.
11)  Kang MI, Baker AR, Dextras CR, Cabarcas SM, Young MR, Colburn NH.
Targeting of Noncanonical Wnt5a Signaling by AP-1 Blocker Dominant-Negative Jun When It Inhibits Skin Carcinogenesis.
Genes Cancer. 3: 37-50, 2012.
12)  Bobe G, Murphy G, Albert PS, Sansbury LB, Young MR, Lanza E, Schatzkin A, Colburn NH, Cross AJ.
Do interleukin polymorphisms play a role in the prevention of colorectal adenoma recurrence by dietary flavonols?.
Eur. J. Cancer Prev. 20: 86-95, 2011.
13)  Wei Q, Jiang H, Xiao Z, Baker A, Young MR, Veenstra TD, Colburn NH.
Sulfiredoxin-Peroxiredoxin IV axis promotes human lung cancer progression through modulation of specific phosphokinase signaling.
Proc. Natl. Acad. Sci. U.S.A. 108: 7004-9, 2011.
14)  Tichelaar JW, Yan Y, Tan Q, Wang Y, Estensen RD, Young MR, Colburn NH, Yin H, Goodin C, Anderson MW, You M.
A dominant-negative c-jun mutant inhibits lung carcinogenesis in mice.
Cancer Prev Res (Phila). 3: 1148-56, 2010.
15)  Camalier CE, Young MR, Bobe G, Perella CM, Colburn NH, Beck GR.
Elevated phosphate activates N-ras and promotes cell transformation and skin tumorigenesis.
Cancer Prev Res (Phila). 3: 359-70, 2010.
16)  Young MR, Santhanam AN, Yoshikawa N, Colburn NH.
Have tumor suppressor PDCD4 and its counteragent oncogenic miR-21 gone rogue?.
Mol. Interv. 10: 76-9, 2010.
17)  Gamero AM, Young MR, Mentor-Marcel R, Bobe G, Scarzello AJ, Wise J, Colburn NH.
STAT2 contributes to promotion of colorectal and skin carcinogenesis.
Cancer Prev Res (Phila). 3: 495-504, 2010.
18)  Kang MI, Henrich CJ, Bokesch HR, Gustafson KR, McMahon JB, Baker AR, Young MR, Colburn NH.
A selective small-molecule nuclear factor-kappaB inhibitor from a high-throughput cell-based assay for.
Mol. Cancer Ther. 8: 571-81, 2009.
19)  Kim YS, Young MR, Bobe G, Colburn NH, Milner JA.
Bioactive food components, inflammatory targets, and cancer prevention.
Cancer Prev Res (Phila). 2: 200-8, 2009.
20)  Mentor-Marcel RA, Bobe G, Barrett KG, Young MR, Albert PS, Bennink MR, Lanza E, Colburn NH.
Inflammation-associated serum and colon markers as indicators of dietary attenuation of colon carcinogenesis in ob/ob mice.
Cancer Prev Res (Phila). 2: 60-9, 2009.
21)  Bobe G, Barrett KG, Mentor-Marcel RA, Saffiotti U, Young MR, Colburn NH, Albert PS, Bennink MR, Lanza E.
Dietary cooked navy beans and their fractions attenuate colon carcinogenesis in azoxymethane-induced ob/ob mice.
Nutr Cancer. 60: 373-81, 2008.
22)  Shen Q, Uray IP, Li Y, Zhang Y, Hill J, Xu XC, Young MR, Gunther EJ, Hilsenbeck SG, Colburn NH, Chodosh LA, Brown PH.
Targeting the activator protein 1 transcription factor for the prevention of estrogen receptor-negative mammary tumors.
Cancer Prev Res (Phila). 1: 45-55, 2008.
23)  Ruocco KM, Goncharova EI, Young MR, Colburn NH, McMahon JB, Henrich CJ.
A high-throughput cell-based assay to identify specific inhibitors of transcription factor AP-1.
Journal of biomolecular screening : the official journal of the Society for Biomolecular Screening. 12: 133-9, 2007.
24)  Hwang SK, Jin H, Kwon JT, Chang SH, Kim TH, Cho CS, Lee KH, Young MR, Colburn NH, Beck GR, Yang HS, Cho MH.
Aerosol-delivered programmed cell death 4 enhanced apoptosis, controlled cell cycle and suppressed AP-1 activity in the lungs of AP-1 luciferase reporter mice.
Gene Ther. 14: 1353-61, 2007.
25)  Matthews CP, Colburn NH, Young MR.
AP-1 a target for cancer prevention.
Current cancer drug targets. 7: 317-24, 2007.
26)  Matthews CP, Birkholz AM, Baker AR, Perella CM, Beck GR, Young MR, Colburn NH.
Dominant-negative activator protein 1 (TAM67) targets cyclooxygenase-2 and osteopontin under conditions in which it specifically inhibits tumorigenesis.
Cancer Res. 67: 2430-8, 2007.
27)  Young MR, Colburn NH.
Fra-1 a target for cancer prevention or intervention.
Gene. 379: 1-11, 2006.
28)  Schmid T, Young MR.
Lights on for low oxygen: a noninvasive mouse model useful for sensing oxygen deficiency.
Mol. Interv. 6: 20-2, 2, 2006.
29)  Shen Q, Zhang Y, Uray IP, Hill JL, Kim HT, Lu C, Young MR, Gunther EJ, Hilsenbeck SG, Chodosh LA, Colburn NH, Brown PH.
The AP-1 transcription factor regulates postnatal mammary gland development.
Dev. Biol. 295: 589-603, 2006.
30)  Hou DX, Kai K, Li JJ, Lin S, Terahara N, Wakamatsu M, Fujii M, Young MR, Colburn N.
Anthocyanidins inhibit activator protein 1 activity and cell transformation: structure-activity relationship and molecular mechanisms.
Carcinogenesis. 25: 29-36, 2004.
31)  Cooper SJ, MacGowan J, Ranger-Moore J, Young MR, Colburn NH, Bowden GT.
Expression of dominant negative c-jun inhibits ultraviolet B-induced squamous cell carcinoma number and size in an SKH-1 hairless mouse model.
Mol. Cancer Res. 1: 848-54, 2003.
32)  Young MR, Yang HS, Colburn NH.
Promising molecular targets for cancer prevention: AP-1, NF-kappa B and Pdcd4.
Trends in molecular medicine. 9: 36-41, 2003.
33)  Thompson EJ, MacGowan J, Young MR, Colburn N, Bowden GT.
A dominant negative c-jun specifically blocks okadaic acid-induced skin tumor promotion.
Cancer Res. 62: 3044-7, 2002.
34)  Young MR, Farrell L, Lambert P, Awasthi P, Colburn NH.
Protection against human papillomavirus type 16-E7 oncogene-induced tumorigenesis by in vivo expression of dominant-negative c-jun.
Mol. Carcinog. 34: 72-7, 2002.
35)  Dhar A, Young MR, Colburn NH.
The role of AP-1, NF-kappaB and ROS/NOS in skin carcinogenesis: the JB6 model is predictive.
Mol. Cell. Biochem. 234-235: 185-93, 2002.
36)  Young MR, Nair R, Bucheimer N, Tulsian P, Brown N, Chapp C, Hsu TC, Colburn NH.
Transactivation of Fra-1 and consequent activation of AP-1 occur extracellular signal-regulated kinase dependently.
Mol. Cell. Biol. 22: 587-98, 2002.
37)  Hsu TC, Nair R, Tulsian P, Camalier CE, Hegamyer GA, Young MR, Colburn NH.
Transformation nonresponsive cells owe their resistance to lack of p65/nuclear factor-kappaB activation.
Cancer Res. 61: 4160-8, 2001.
38)  Hsu TC, Young MR, Cmarik J, Colburn NH.
Activator protein 1 (AP-1)- and nuclear factor kappaB (NF-kappaB)-dependent transcriptional events in carcinogenesis.
Free Radic. Biol. Med. 28: 1338-48, 2000.
39)  Li JJ, Cao Y, Young MR, Colburn NH.
Induced expression of dominant-negative c-jun downregulates NFkappaB and AP-1 target genes and suppresses tumor phenotype in human keratinocytes.
Mol. Carcinog. 29: 159-69, 2000.
40)  Pennie WD, Hegamyer GA, Young MR, Colburn NH.
Specific methylation events contribute to the transcriptional repression of the mouse tissue inhibitor of metalloproteinases-3 gene in neoplastic cells.
Cell Growth Differ. 10: 279-86, 1999.
41)  Young MR, Li JJ, Rincón M, Flavell RA, Sathyanarayana BK, Hunziker R, Colburn N.
Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion.
Proc. Natl. Acad. Sci. U.S.A. 96: 9827-32, 1999.
42)  Watts RG, Huang C, Young MR, Li JJ, Dong Z, Pennie WD, Colburn NH.
Expression of dominant negative Erk2 inhibits AP-1 transactivation and neoplastic transformation.
Oncogene. 17: 3493-8, 1998.
43)  Huang C, Ma WY, Young MR, Colburn N, Dong Z.
Shortage of mitogen-activated protein kinase is responsible for resistance to AP-1 transactivation and transformation in mouse JB6 cells.
Proc. Natl. Acad. Sci. U.S.A. 95: 156-61, 1998.
Click Here to View Collapsed Bibliography.

This page was last updated on 7/14/2014.